

## Could you bring patient advocacy experience to help us develop and deliver a programme of trials for patients with triple negative breast cancer?



We are looking for people with patient advocate experience in breast cancer research. We would like you to bring your patient advocacy experience for a new programme of trials in triple negative breast cancer as part of an 'Advocate Advisory Group'.

We would like to learn from your experience and expertise to develop a programme of research to help improve treatment for patients with triple negative breast cancer. Researchers from across the UK are working together, cooperatively, to design several trials that would cover the entire patient treatment and care pathway from diagnosis through to long-term follow-up. This is called the Triple Negative Breast Cancer Federated Platform. The main aim is to improve patient treatment and outcomes, but we also think that this approach will help increase access to trials for patients at key steps in their treatment pathway. By working together to design this programme of research it is thought it will help avoid similar but separate studies being set-up by different research organisations. It would also allow information collected in each trial to be shared more easily between researchers.



One of the trials under the Triple Negative Breast Cancer Federated Platform aims to optimise treatment with immunotherapy. Immunotherapy drugs use our immune system to fight cancer. It works by helping the immune system to recognise and attack cancer cells. As with all drugs, immunotherapy is associated with side effects and some of these can last a long time. This trial aims to find out whether some patients, who do not have any cancer cells remaining at surgery following treatment, can safely avoid having further immunotherapy after surgery.



The Advocate Advisory Group will include experienced patient advocates in breast cancer research to allow consideration of all aspects of the planned programme of trials. You will work with Professor Judith Bliss (Clinical Trials and Statistics Unit at the Institute of Cancer Research) and several oncologists and

surgeons from across the UK who are leaders in breast cancer research, to develop and deliver the trials over coming years. We would like you to consider all aspects of the trials from the patient's perspective and bring the ability to represent perspectives beyond your own personal experience. It is estimated there will be at approximately 6 (online) meetings per year (during office hours) with additional correspondence between meetings.



We can offer you reimbursement for your time and expenses. If you would like to find out more, please email: [TNBCplatform-icrctsu@icr.ac.uk](mailto:TNBCplatform-icrctsu@icr.ac.uk)